Patrick Flume to Lung
This is a "connection" page, showing publications Patrick Flume has written about Lung.
Connection Strength
2.089
-
Bronchodilators in cystic fibrosis: a critical analysis. Expert Rev Respir Med. 2017 01; 11(1):13-20.
Score: 0.379
-
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9.
Score: 0.341
-
Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis? Am J Respir Crit Care Med. 2014 Mar 01; 189(5):510-1.
Score: 0.315
-
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response. J Cyst Fibros. 2022 07; 21(4):588-593.
Score: 0.135
-
Chest Computed Tomography Features of Nontuberculous Mycobacterial Pulmonary Disease Versus Asymptomatic Colonization: A Cross-sectional Cohort Study. J Thorac Imaging. 2022 May 01; 37(3):140-145.
Score: 0.131
-
Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. Eur Respir J. 2020 04; 55(4).
Score: 0.120
-
Pulmonary Complications of Cystic Fibrosis. Semin Respir Crit Care Med. 2019 12; 40(6):804-809.
Score: 0.117
-
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 06; 49(6).
Score: 0.099
-
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):783-790.
Score: 0.091
-
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb; 169:116-21.e2.
Score: 0.088
-
Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1.
Score: 0.087
-
Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010 Aug 01; 182(3):298-306.
Score: 0.061
-
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. J Cyst Fibros. 2022 07; 21(4):594-599.
Score: 0.034
-
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation. J Cyst Fibros. 2022 07; 21(4):574-580.
Score: 0.034
-
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 10 30; 69(10):1812-1816.
Score: 0.029
-
"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis. J Clin Microbiol. 2018 09; 56(9).
Score: 0.027